Study aid only. Verify against current guidelines, primary literature, staging manuals, and prescribing information before clinical use.

← All algorithms  ·  Related notes →

Advanced Urothelial Carcinoma — Systemic Therapy

First-line Second-line SECOND-LINE Advanced urothelial carcinoma First-line Later-line Preferred Enfortumab vedotin + pembrolizumab EV-302 ↗ Cisplatin-fit Cisplatin chemo → maint avelumab JAVELIN Bladder 100 ↗ Cis-ineligible Carboplatin chemo → maint avelumab JAVELIN Bladder 100 ↗ ADC Enfortumab vedotin EV-301 ↗ FGFR3 Erdafitinib THOR ↗ ADC Sacituzumab govitecan TROPHY-U-01 ↗ IO Pembrolizumab KEYNOTE-045 ↗